512 related articles for article (PubMed ID: 27539839)
21. Can we differentiate histologic subtypes of neuroendocrine tumour liver metastases at a single phase contrast-enhanced CT-correlation with Ga-68 DOTATATE PET/CT findings.
Gulpinar B; Peker E; Soydal C; Araz M; Elhan AH
Br J Radiol; 2020 Feb; 93(1106):20190735. PubMed ID: 31922897
[TBL] [Abstract][Full Text] [Related]
22. The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors.
Haug AR; Cindea-Drimus R; Auernhammer CJ; Reincke M; Wängler B; Uebleis C; Schmidt GP; Göke B; Bartenstein P; Hacker M
J Nucl Med; 2012 Nov; 53(11):1686-92. PubMed ID: 22984220
[TBL] [Abstract][Full Text] [Related]
23. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.
Kayani I; Conry BG; Groves AM; Win T; Dickson J; Caplin M; Bomanji JB
J Nucl Med; 2009 Dec; 50(12):1927-32. PubMed ID: 19910422
[TBL] [Abstract][Full Text] [Related]
24. The added value of
Kazmierczak PM; Rominger A; Wenter V; Spitzweg C; Auernhammer C; Angele MK; Rist C; Cyran CC
Eur Radiol; 2017 Apr; 27(4):1676-1684. PubMed ID: 27436022
[TBL] [Abstract][Full Text] [Related]
25. Impact of Point-Spread Function Reconstruction on
You H; Sanli Y; Subramaniam RM
AJR Am J Roentgenol; 2019 Sep; 213(3):683-688. PubMed ID: 31120789
[No Abstract] [Full Text] [Related]
26. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
[TBL] [Abstract][Full Text] [Related]
27. Differences in tumor-to-normal organ SUV ratios measured with 68 Ga-DOTATATE PET compared with 177 Lu-DOTATATE SPECT in patients with neuroendocrine tumors.
Wong KK; Frey KA; Niedbala J; Kaza RK; Worden FP; Fitzpatrick KJ; Dewaraja YK
Nucl Med Commun; 2022 Aug; 43(8):892-900. PubMed ID: 35703269
[TBL] [Abstract][Full Text] [Related]
28.
Sharma R; Wang WM; Yusuf S; Evans J; Ramaswami R; Wernig F; Frilling A; Mauri F; Al-Nahhas A; Aboagye EO; Barwick TD
Radiother Oncol; 2019 Dec; 141():108-115. PubMed ID: 31542317
[TBL] [Abstract][Full Text] [Related]
29. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
[TBL] [Abstract][Full Text] [Related]
30. Increased Activity Due to Fractures Does Not Significantly Affect the Accuracy of 68Ga-DOTATATE PET/CT in the Detection of Culprit Tumor in the Evaluation of Tumor-Induced Osteomalacia.
Ding J; Hu G; Wang L; Li F; Huo L
Clin Nucl Med; 2018 Dec; 43(12):880-886. PubMed ID: 30273206
[TBL] [Abstract][Full Text] [Related]
31. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours.
Ambrosini V; Nanni C; Zompatori M; Campana D; Tomassetti P; Castellucci P; Allegri V; Rubello D; Montini G; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):722-7. PubMed ID: 20107793
[TBL] [Abstract][Full Text] [Related]
32. A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on
Gålne A; Almquist H; Almquist M; Hindorf C; Ohlsson T; Nordenström E; Sundlöv A; Trägårdh E
J Nucl Med; 2019 Dec; 60(12):1717-1723. PubMed ID: 31000584
[TBL] [Abstract][Full Text] [Related]
33.
Loft M; Carlsen EA; Johnbeck CB; Johannesen HH; Binderup T; Pfeifer A; Mortensen J; Oturai P; Loft A; Berthelsen AK; Langer SW; Knigge U; Kjaer A
J Nucl Med; 2021 Jan; 62(1):73-80. PubMed ID: 32444370
[No Abstract] [Full Text] [Related]
34. Prognostic value of somatostatin receptor expressing tumor volume calculated from
Toriihara A; Baratto L; Nobashi T; Park S; Hatami N; Davidzon G; Kunz PL; Iagaru A
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2244-2251. PubMed ID: 31350603
[TBL] [Abstract][Full Text] [Related]
35. Clinical value of ⁶⁸Ga-DOTATATE-PET/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET).
Albanus DR; Apitzsch J; Erdem Z; Erdem O; Verburg FA; Behrendt FF; Mottaghy FM; Heinzel A
Eur J Radiol; 2015 Oct; 84(10):1866-72. PubMed ID: 26152870
[TBL] [Abstract][Full Text] [Related]
36. High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT.
Werner RA; Derlin T; Rowe SP; Bundschuh L; Sheikh GT; Pomper MG; Schulz S; Higuchi T; Buck AK; Bengel FM; Bundschuh RA; Lapa C
J Nucl Med; 2021 Apr; 62(4):514-520. PubMed ID: 32859702
[TBL] [Abstract][Full Text] [Related]
37. Localization of Unknown Primary Site with
Menda Y; O'Dorisio TM; Howe JR; Schultz M; Dillon JS; Dick D; Watkins GL; Ginader T; Bushnell DL; Sunderland JJ; Zamba GKD; Graham M; O'Dorisio MS
J Nucl Med; 2017 Jul; 58(7):1054-1057. PubMed ID: 28153957
[TBL] [Abstract][Full Text] [Related]
38. [(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer.
Vrachimis A; Stegger L; Wenning C; Noto B; Burg MC; Konnert JR; Allkemper T; Heindel W; Riemann B; Schäfers M; Weckesser M
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1765-72. PubMed ID: 27059853
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
[TBL] [Abstract][Full Text] [Related]
40. The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours.
Łapińska G; Bryszewska M; Fijołek-Warszewska A; Kozłowicz-Gudzińska I; Ochman P; Sackiewicz-Słaby A
Nucl Med Rev Cent East Eur; 2011; 14(1):16-20. PubMed ID: 21751167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
